

1 ***APOE* Genotype-specific Methylation Patterns are Linked to Alzheimer**

2 **Disease Pathology and Estrogen Response**

3
4 Rebecca Panitch¹, Nathan Sahelijo¹, Junming Hu¹, the Alzheimer's Disease Neuroimaging
5 Initiative, Kwangsik Nho^{10,11}, David A. Bennett¹², Kathryn L. Lunetta⁶, Rhoda Au^{2,3,7}, Thor D.
6 Stein^{5,8,9}, Lindsay A. Farrer^{1,2,4,6,7,*}, Gyungah R. Jun^{1,4,6,*}

7
8 Departments of ¹Medicine (Biomedical Genetics), ²Neurology, ³Anatomy & Neurobiology,
9 ⁴Ophthalmology, ⁵Pathology & Laboratory Medicine, and Boston University School of
10 Medicine, 72 East Concord Street, Boston, MA 02118, USA.

11 Departments of ⁶Biostatistics and ⁷Epidemiology, Boston University School of Public Health,
12 715 Albany Street, Boston, MA 02118, USA.

13 ⁸VA Bedford Healthcare System, Bedford, MA 01730, USA.

14 ⁹VA Boston Healthcare Center, Boston, MA 02130, USA.

15 ¹⁰Department of Radiology and Imaging Sciences and Indiana Alzheimer's Disease Research
16 Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

17 ¹¹Center for Computational Biology and Bioinformatics, Indiana University School of Medicine,

18 ¹²Rush Alzheimer's Disease Center, Rush University Medical Center, 1750 W. Harrison Street,
19 Suite 1000, Chicago, IL 60612, USA.

20
21 * Address Correspondence to:

22 Lindsay A. Farrer, PhD, Department of Medicine (Biomedical Genetics), Boston University
23 School of Medicine, 72 East Concord Street, Boston, MA 02118, USA 02118, email:
24 farrer@bu.edu;

25 Gyungah R. Jun, PhD, Department of Medicine (Biomedical Genetics), Boston University
26 School of Medicine, 72 East Concord Street, Boston, MA 02118, USA 02118, email:
27 gyungah@bu.edu.

28 **Abstract:**

29 The joint effects of *APOE* genotype and DNA methylation on Alzheimer disease (AD) risk is
30 relatively unknown. We conducted genome-wide methylation analyses using 2,021 samples in
31 blood (91 AD cases, 329 mild cognitive impairment, 1,391 controls) and 697 samples in brain
32 (417 AD cases, 280 controls). We identified differentially methylated levels in AD compared to
33 controls in an *APOE* genotype-specific manner at 25 cytosine-phosphate-guanine (CpG) sites in
34 brain and 36 CpG sites in blood. Additionally, we identified seven CpG sites in the *APOE* region
35 containing *TOMM40*, *APOE*, and *APOC1* genes with $P < 5 \times 10^{-8}$ between *APOE* $\epsilon 4$ carriers and
36 non-carriers in brain or blood. In brain, the most significant CpG site hypomethylated in $\epsilon 4$
37 carriers compared to non-carriers) was from the *TOMM40* in the total sample, while most of the
38 evidence was derived from AD cases. However, the CpG site was not significantly modulating
39 expression of these three genes in brain. Three CpG sites from the *APOE* were hypermethylated
40 in *APOE* $\epsilon 4$ carriers in brain or blood compared in $\epsilon 4$ non-carriers and nominally significant with
41 *APOE* expression in brain. Three CpG sites from the *APOC1* were hypermethylated in blood,
42 which one of the 3 CpG sites significantly lowered *APOC1* expression in blood using all subjects
43 or $\epsilon 4$ non-carriers. Co-methylation network analysis in blood and brain detected eight
44 methylation networks associated with AD and *APOE* $\epsilon 4$ status. Five of the eight networks
45 included genes containing network CpGs that were significantly enriched for estradiol
46 perturbation, where four of the five networks were enriched for the estrogen response pathway.
47 Our findings provide further evidence of the role of *APOE* genotype on methylation levels
48 associated with AD, especially linked to estrogen response pathway.

49 **Introduction**

50 Alzheimer disease (AD) is a neurodegenerative disorder characterized neuropathologically by
51 neurofibrillary tangles and amyloid plaques [1]. The apolipoprotein E (*APOE*) ϵ 4 variant is the
52 strongest genetic risk factor for late-onset AD, while the ϵ 2 variant has been shown to confer
53 protection against AD, in a dose-dependent manner [2,3,4]. Single copies of the ϵ 4 and ϵ 2 alleles
54 are associated with 3 to 4-fold increased and 0.61-fold decreased risk of AD, respectively.
55 Previous studies identified *APOE* genotype-specific mechanisms including the complement
56 pathway and blood-brain barrier dysfunction [5,6,7].

57 Large-scale genome-wide association studies (GWAS) have identified contributions to
58 AD risk from more than 75 independent loci, but the large portion of heritability of the disease is
59 unexplained [8]. Emerging omics technologies have prompted investigations of gene expression
60 and epigenetic profiles at the tissue and cellular levels. For example, it has been shown that the
61 degree of methylation of cytosine-phosphate-guanine (CpG) dinucleotides in brain differ
62 between AD cases and controls in novel regions as well as in loci previously associated with AD
63 risk such as *BINI* [9]. Methylation levels at multiple CpG sites assessed in peripheral blood have
64 also been associated with cognitive decline and AD progression [10].

65 Several CpG sites in the *APOE* region are differentially methylated in AD cases
66 compared to controls, and distinct methylation patterns have been observed between persons
67 with the ϵ 3/ ϵ 3 and ϵ 3/ ϵ 4 genotypes [11]. In addition, the *APOE* region has been shown to be
68 differentially methylated between healthy ϵ 2 and ϵ 4 carriers in blood [12]. However, despite
69 these findings, the effect of *APOE* genotypes, especially on the genome-wide level for AD risk
70 remains relatively unknown. Here, we analyzed methylation array data from blood and brain

71 tissue in three datasets to discover *APOE* genotype-dependent genome-wide associations of
72 methylation with AD risk and related traits, as well as co-methylation networks.

73

74 **Methods**

75 **Sources of Methylation and Phenotypic Data**

76 Data were obtained for participants of three cohort studies including the Religious Orders Study
77 and Rush Memory and Aging Project (ROSMAP), Alzheimer’s Disease Neuroimaging Initiative
78 (ADNI), and Framingham Heart Study (FHS).

79 **Religious Orders Study and Rush Memory and Aging Project (ROSMAP):** Clinical,

80 neuropathological information, *APOE* genotyping, and preprocessed, quality controlled, and
81 normalized brain HumanMethylation450 BeadChip methylation array data derived from
82 dorsolateral prefrontal cortex area tissue donated by 697 ROSMAP participants (417 autopsy-
83 confirmed AD cases and 280 controls) [13,14,15] were obtained from the CommonMind
84 Consortium portal (<http://www.synapse.org>) (**Supplementary Table 1**). AD diagnosis was
85 determined using National Institute of Aging (NIA) Reagan criteria for intermediate or high
86 probability of AD [16]. AD-related traits included Braak staging for neurofibrillary tangles [17]
87 and the Consortium to Establish a Registry for Alzheimer Disease (CERAD) semi-quantitative
88 criteria for measuring neuritic plaques (CERAD Score) [18]. ROS and MAP were both approved
89 by an Institutional Review Board of Rush University Medical Center. All participants signed an
90 informed consent, Anatomic Gift Act, and repository consent.

91 **Alzheimer’s Disease Neuroimaging Initiative (ADNI):** Infinium® MethylationEPIC BeadChip

92 beta values and phenotype data were obtained from the LONI website (<http://adni.loni.usc.edu>)
93 for 630 ADNI participants including 91 with a clinical AD diagnosis, 329 with mild cognitive

94 impairment (MCI), and 210 controls [10]. Methylation array iDAT files were processed and
95 normalized using watermelon [19]. Because methylation was measured in DNA extracted from
96 blood specimens obtained at multiple examinations, methylation data from the earliest timepoint
97 were analyzed. Among the available endophenotypic data, analyses included magnetic resonance
98 imaging (MRI) volumetric measures of ventricles, and hippocampus, and entorhinal thickness, as
99 well as neuropsychological test scores consisted of the Alzheimer’s Disease Assessment Scale –
100 13 item (ADAS13), Clinical Dementia Rating Scale Sum of Boxes (CDRSB), logical memory -
101 delayed recall (LDELTOTAL), Rey Auditory Verbal Learning Test (RAVLT) immediate,
102 RAVLT learning, and RAVLT percent forgetting.

103 **Framingham Heart Study (FHS):** Cognitive test and normalized HumanMethylation450
104 BeadChip methylation array data were obtained for 1,391 cognitively healthy participants from
105 the generation 3 cohort in FHS [20]. Cognitive test scores at the same time point of methylation
106 measurement included the Paired Associate Learning - Recognition (PASr) test, Logical
107 Memories – Immediate Recall (LMi) test, Logical Memories – Delayed Recall (LMd) test,
108 Similarities Test (SIM), Visual Reproductions – Delayed Recall (VRd), Trail A (trailsA) test, the
109 animal portion of the Verbal Fluency Test (FAS_animal), and Boston Naming Test (BNT30).

110 **Differential Methylation Analysis**

111 Differential methylation between AD and control samples was performed in the ADNI and
112 ROSMAP datasets using the LIMMA software [21]. The methylation percentage of each CpG
113 site, defined as the proportion of total signal from the methylation-specific probe, was compared
114 between AD cases and controls using linear regression models including sex, age, and batch as
115 covariates. Genome-wide methylation analyses were conducted in the total sample and
116 separately within *APOE* $\epsilon 4$ carriers ($\epsilon 2/\epsilon 4$, $\epsilon 3/\epsilon 4$, and $\epsilon 4/\epsilon 4$) and non-carriers ($\epsilon 2/\epsilon 2$, $\epsilon 2/\epsilon 3$, and

117 $\epsilon 3/\epsilon 3$). Genome-wide methylation analysis between *APOE* $\epsilon 4$ carriers and non-carriers was
118 performed in the ADNI and ROSMAP datasets using LIMMA and regression models including
119 terms for age, sex and batch in the total sample and separately within AD and control groups.
120 Genome-wide methylation analysis between *APOE* $\epsilon 4$ carriers and non-carriers for each CpG
121 site was conducted in FHS using lme4 package in R and a linear mixed effect model
122 incorporating a genetic relatedness matrix (GRM) as a random effect with sex and age at exam as
123 covariates. The GRM was generated using genetic dosage data and the software GCTA [22] to
124 account for familial relationships among 8,481 FHS participants.

125 **Association of Methylation with Expression of Genes in the *APOE* Region**

126 RNA-sequencing (RNA-seq) data derived from ROSMAP brains were obtained and processed as
127 previously described [7]. Matched RNA-seq and methylation data were available for 510
128 ROSMAP participants (297 AD cases, 213 controls). Normalized gene-expression microarray
129 data were obtained from the LONI website (<http://adni.loni.usc.edu>) for 159 ADNI subjects (42
130 AD cases, 117 controls) who also had matching methylation array data. Significantly methylated
131 CpG sites between *APOE* $\epsilon 4$ -carriers and non-carriers ($p=5.0 \times 10^{-8}$) in *APOE* region genes
132 (*NECTIN2*, *APOC1*, *APOE*, and *TOMM40*) were selected for further analysis. The association of
133 gene expression level and methylation levels at the CpG sites in the *APOE* region was evaluated
134 using linear regression models with covariates including age, sex, RNA integrity number (RIN),
135 RNA batch, and methylation batch. Post-mortem interval (PMI) was included as an additional
136 covariate in analyses of the ROSMAP dataset that had this information. Analyses were
137 performed in the total sample and separately within *APOE* $\epsilon 4$ carriers and non-carriers.

138 **Association of Methylation with Phenotypic Traits**

139 Quantitative or semi-quantitative traits were rank-transformed after adjusting for age and sex as
140 previously described [23]. In the ROSMAP dataset, the association of CpG site methylation with
141 rank-transformed Braak stage and CERAD score was assessed using regression models including
142 batch as a covariate. In the ADNI dataset, the association of CpG site methylation with cognitive
143 test scores and imaging phenotypes were assessed using regression models including covariates
144 of batch and education for cognitive traits and of batch and intracranial volume for imaging
145 phenotypes. In the FHS dataset, we tested the association of methylation with cognitive test
146 scores using a linear mixed effects model accounting for education and family structure with the
147 GRM as covariates. Association models were evaluated in the total sample and separately within
148 groups of *APOE* $\epsilon 4$ carriers and non-carriers.

149 **Co-methylation Network Analysis**

150 Co-methylation networks were generated with differentially methylated CpG sites ($P < 0.05$)
151 between *APOE* $\epsilon 4$ carriers and non-carriers in the ADNI and ROSMAP datasets using the
152 weighted correlation network analysis (WGCNA) program [24]. Analyses in the ADNI dataset
153 also included data from 329 subjects with MCI. We selected four and six soft-power parameters
154 in the ADNI and ROSMAP datasets, respectively, as previously described [5]. CpG percentages
155 were hierarchically clustered using a dissimilarity topological overlap matrix (TOM). Modules
156 with a minimum of 100 CpG sites were created using dynamic tree cutting, networks with
157 similar eigenvalues and a height of 0 were merged using WGCNA's mergeCloseModules
158 function. The signedKME function assigned fuzzy module membership. We identified networks
159 exhibiting significantly different methylation levels of eigenvalues between *APOE* $\epsilon 4$ carriers
160 and non-carriers and between AD cases and controls, determined by a student's t-test, which
161 were selected for subsequent analysis. Biological pathways (MSigDB_Hallmark_2020) and drug

162 perturbations (Drug_Perturbations_from_GEO_2014) for each network were identified using the
163 EnrichR program applied to genes containing CpG sites in significant networks [25]. QIAGEN
164 Ingenuity Pathway Analysis (IPA) software was used to create a biological network containing
165 overlapping genes across modules from the EnrichR analysis.

166

167 **Results**

168 **Differentially methylated CpG sites between AD cases and controls**

169 Methylation levels in 697 brain samples from ROSMAP participants and 301 blood samples
170 from ADNI participants were compared between AD cases and controls in the total sample, and
171 within *APOE* $\epsilon 4$ carrier and non-carrier subgroups (**Figure 1a and Supplementary Table 1**). In
172 the combined datasets, there were no genome-wide significant ($P < 5 \times 10^{-8}$) differentially
173 methylated CpG sites between AD cases and controls in those with or without $\epsilon 4$. However,
174 analysis of the brain data revealed, moderately different ($P < 10^{-5}$) methylation levels at 3 CpG
175 sites among $\epsilon 4$ carriers and 22 CpG sites among $\epsilon 4$ non-carriers (**Table 1 and Supplementary**
176 **Figure 1a**). Of the 25 CpG sites that were differentially methylated in either *APOE* genotype
177 subgroup, approximately half (13 CpG sites) were moderately differentially methylated in the
178 total sample. Most of the CpG sites that were differentially methylated among $\epsilon 4$ non-carriers
179 ($20/25 = 80\%$) were significantly associated ($P < 2.0 \times 10^{-3}$) with Braak stage and/or CERAD score
180 (**Figure 1b and Supplementary Table 2**). Methylation levels of two intergenic CpG sites
181 (cg05731218 and cg12307200) were lower in AD cases compared to controls in the total sample
182 and associated with both Braak stage and CERAD score at a genome-wide significance level
183 ($P < 5 \times 10^{-8}$). The most significant association of methylation CpG sites located within genes were

184 observed for cg10907744 in *GPR133* with Braak stage ($P=5.8 \times 10^{-6}$) and CERAD score
185 ($P=4.6 \times 10^{-6}$) and for cg19987111 in *CHSY1* with Braak stage ($P=8.5 \times 10^{-8}$).

186 Moderately significant differential methylation between AD cases and controls from
187 blood were observed in 21 CpG sites among $\epsilon 4$ carriers and 15 CpG sites in $\epsilon 4$ non-carriers
188 (**Supplementary Table 3 and Supplementary Figure 1b**). In contrast to the findings in the
189 brain data, none of these CpG sites were improved in significance in the total sample
190 (**Supplementary Table 3**). Methylation of the 15 CpG sites, eleven among $\epsilon 4$ carriers and four
191 among $\epsilon 4$ non-carriers, was significantly (multiple testing correction $P < 1.4 \times 10^{-3}$) associated with
192 performance on global and domain-specific cognitive tests, and/or MRI brain imaging measures
193 (**Figure 1c**). Methylation of the CpG site cg09825488 in *EXO5* was increased in AD cases
194 compared to controls in $\epsilon 4$ non-carriers ($P=2.9 \times 10^{-6}$, **Supplementary Table 3**) and significantly
195 associated with both global cognitive tests and several domain specific cognitive tests
196 (**Supplementary Table 4**). Methylation of three CpG sites (cg00198525, cg18714484, and
197 cg25190513) in $\epsilon 4$ carriers was significantly associated with the volume of cortical brain regions
198 (**Supplementary Table 4**). Methylation at the cg18714484 in *CHEK1* was decreased in AD
199 cases compared to controls in $\epsilon 4$ carriers ($P=2.2 \times 10^{-6}$; **Supplementary Table 3**) and inversely
200 associated with global cognitive ($P=1.8 \times 10^{-5}$), memory performance (4.2×10^{-5}) and ventricle
201 volume ($P=8.1 \times 10^{-4}$).

202

203 **Differentially methylated CpG sites between *APOE* $\epsilon 4$ carriers and non-carriers**

204 Eight CpG sites were significantly differentially methylated (5×10^{-8}) between *APOE* $\epsilon 4$ carriers
205 and non-carriers in the ADNI, FHS, and ROSMAP datasets, and seven of the 8 sites are located
206 within the *APOE* region (chr19:45380000-45430000) (**Table 2 and Figure 2a**). In brain,

207 cg02613937 located in *TOMM40* was the most significant CpG site (hypomethylated in $\epsilon 4$
208 carriers compared to non-carriers) in the total sample ($P=1.3 \times 10^{-13}$) and most of the evidence was
209 derived from AD cases ($P=7.0 \times 10^{-13}$). Methylation at the cg02613937 was not significantly
210 associated with expression of genes in the *APOE* region (**Figure 2b**). In contrast, three CpG sites
211 from the *APOE* were hypermethylated in *APOE* $\epsilon 4$ carriers in brain (cg14123992, cg04406254)
212 and blood (cg06750524) compared in $\epsilon 4$ non-carriers (**Table 2, Figure 2a**). Methylation at both
213 *APOE* CpG sites in brain was nominally associated ($P < 0.05$) with the *APOE* expression in $\epsilon 4$
214 carriers only (**Figure 2b**). Three CpG sites from the *APOC1* in blood were significantly
215 hypomethylated in $\epsilon 4$ carriers compared to non-carriers in either AD cases (cg07773593) or
216 controls (cg23270113 and cg05644480). Methylation of cg07773593 was nominally significant
217 ($p < 0.05$) with lower *APOC1* expression in the total sample and $\epsilon 4$ non-carriers (**Supplementary**
218 **Figure 2**).

219 Among the significant CpG sites in the *APOE* region between $\epsilon 4$ carriers and non-carriers
220 in the FHS dataset (**Table 2**), increased methylation in the cg06750524 was associated with poor
221 memory performance measured by the VRd ($P=0.04$) test in FHS *APOE* $\epsilon 4$ carriers (**Figure 2c**
222 **and Supplementary Table 5**). Increased methylation of cg23270113 and cg05644480 from the
223 gene *APOC1* was significantly associated with worse performance on trailsA ($P=6.9 \times 10^{-3}$), PASr
224 ($P=6.7 \times 10^{-3}$), and BNT30 ($P=0.01$) tests in $\epsilon 4$ non-carriers. In *APOE* $\epsilon 4$ carriers, lower
225 methylation at cg23270113 was associated with poor memory performance measured by the
226 LMd ($P=0.05$) and LMi ($P=0.05$) tests, and lower methylation at cg05644480 was associated
227 with poor performance on the SIM ($P=0.05$).

228

229 **Co-Methylation Networks**

230 The average methylation level for each of five networks from brain data and three networks from
231 blood data was significantly different between AD and control subjects as well as between $\epsilon 4$
232 carriers and non-carriers (**Table 3, Supplementary Figure 3, and Supplementary Figure 4**).
233 Five networks (mod2, mod3, mod4, mod5, and mod8) were significantly enriched for eleven
234 pathways (**Figure 3a**). These five networks contained gene-sets including 60 genes that overlap
235 the networks and whose expression levels are modified by estradiol (**Figure 3b and**
236 **Supplementary Table 6**). These 60 genes were biologically connected as a subnetwork (**Figure**
237 **3c**). Four of these networks (excluding mod5) were enriched for the estrogen response early
238 pathway (**Table 3 and Figure 3a**). *GPR133*, a member of mod2 and mod3 networks, was
239 differentially methylated between AD cases and controls lacking $\epsilon 4$ ($P=6.4 \times 10^{-6}$) and
240 significantly associated with Braak stage ($P=5.8 \times 10^{-6}$) and CERAD score ($P=4.6 \times 10^{-6}$) (**Table 1**
241 **and Supplementary Table 2**). Mod5, the only network not enriched for estrogen response early,
242 was uniquely enriched for the E2F target pathway and for seven unique drug perturbation sets
243 (**Table 3, Figure 3a, and Figure 3b**). Mod2 was enriched for estradiol as well as enriched for
244 the complement pathway, mitotic spindles, and TGF-beta signaling (**Figure 3a and Figure 3b**).
245 Mod8 was the only blood network showing significant enrichment for drug perturbations and
246 biological pathways that overlapped significant modules derived from brain (**Figure 3a and**
247 **Figure 3b**).

248

249 **Discussion**

250 We identified 25 CpG sites in brain and 36 CpG sites in blood that were differentially methylated
251 in AD cases compared to controls in an *APOE* genotype-specific manner. Multiple CpG sites in
252 the *APOE* region were differentially methylated between $\epsilon 4$ carriers and non-carriers in brain or

253 blood. Methylation of several of these CpG sites in blood was significantly associated with
254 performance on cognitive tests in either $\epsilon 4$ carriers or non-carriers. Lastly, we derived eight
255 unique co-methylation networks across blood and brain showing significant differential
256 methylation patterns between AD cases and controls and between $\epsilon 4$ carriers and non-carriers.
257 Five of eight (62.5%) networks included genes enriched for an estradiol drug perturbation gene-
258 set and four of these 5 networks were involved in estrogen response pathway. These findings
259 suggest that AD-related methylation patterns are dependent on *APOE* genotype and may be
260 targeted by estrogen modulating drugs.

261 CpG sites in *GPR133* and *CHSY1* were hypermethylated in brain from AD cases lacking
262 *APOE* $\epsilon 4$ and associated with measures of plaque and tangle pathology. *GPR133* is a member of
263 the adhesion G protein-coupled receptor family, several of which have been implicated in AD
264 and proposed as potential drug targets for neurological disease [26]. A deletion in *CHSY1* causes
265 an increased inflammatory response and hippocampal neurodegeneration in mice [27]. We also
266 observed blood hypomethylation at CpG sites from the *CHEK1* gene in AD cases carrying *APOE*
267 $\epsilon 4$. *CHEK1* induces astrogliosis in AD brains and inhibits PP2A which was linked in *APOE*
268 genotype-specific patterns to AD and AD-related traits by GWAS, gene expression analysis, and
269 experimental studies [6,28].

270 Association of AD with variants in the *APOE* region has been extensively evaluated [29].
271 While the link between *APOE* isoforms and AD risk is well established, independent
272 associations for AD with other genes near the *APOE* gene including *TOMM40* and *APOC1* are
273 less conclusive because they often do not replicate across ethnic populations and are confounded
274 by high linkage disequilibrium with *APOE* variants [30,31]. However, methylation studies have
275 consistently shown unique and strong differential methylation patterns by *APOE* genotype in AD

276 cases and controls [11,12]. We confirmed decreased methylation on *APOC1* in blood and
277 increased methylation on *APOE* in brain among $\epsilon 4$ carriers compared to non-carriers, while
278 decreased methylation of $\epsilon 4$ carriers on *TOMM40* in brain. These results suggest possible distinct
279 contributions of the genes in the *APOE* region between blood and brain tissues through
280 differential regulation on methylation sites to AD risk. Future studies are necessary to understand
281 the exact mechanisms involved with methylation and AD between blood and brain tissues in an
282 *APOE* genotype-specific manner.

283 We identified pathways enriched for genes in *APOE* genotype and AD-specific co-
284 methylation networks that were derived from differentially methylated CpG sites between $\epsilon 4$
285 carriers and non-carriers in brain or blood. One of the brain networks was enriched for genes in
286 complement pathway that was previously linked to AD in an *APOE* genotype-specific manner
287 [5,6]. Five of the eight *APOE* $\epsilon 4$ associated networks showed significant enrichment with genes
288 perturbed by a drug, estradiol. Estradiol has been associated with increased cognitive function in
289 both animals and humans [32]. Loss of estrogen in post-menopausal women has been associated
290 with increased AD risk [33] and estrogen replacement therapy has shown to decrease AD risk in
291 post-menopausal women [34], particularly among those under age 64 [35]. Furthermore, the
292 effect of estrogen use on AD risk may be limited to $\epsilon 4$ non-carriers [36]. A recent study showed
293 estrogen decreased amyloid- β accumulation in the hippocampus and cortex in mice lacking $\epsilon 4$
294 [37].

295 Our study has several limitations. First, methylation data from a microarray platform in
296 ADNI participants was different from the one used by FHS and ROSMAP. Therefore, direct
297 replication of each CpG site among these studies was limited. Second, none of the FHS
298 participants with methylation data had AD due to their relatively young age. Alternatively, we

299 evaluated cognitive performance data which served as a robust AD endophenotype. Third,
300 pathway enrichment analysis was conducted using genes with network CpG sites under the
301 assumption of each CpG site directly modulating the corresponding gene. This assumption may
302 not hold when the CpG site regulates a long-distant gene. Fourth, phenotype data were not
303 comparable across datasets; in particular, neuropathological measures (i.e., Braak stage and
304 CERAD score) were available for ROSMAP, whereas ADNI and FHS featured cognitive test
305 data. Finally, the datasets included in this study were too small to account for sex differences
306 after stratification by *APOE* genotype or AD status. As a result, we were unable to evaluate sex
307 effect, especially genes involved in estrogen response pathways.

308 In conclusion, we identified differentially methylated CpG sites in many genes including
309 *APOE* that were also associated with AD and related traits. Many of these associations were
310 *APOE* genotype- or tissue-specific. AD and *APOE* genotype-specific methylation networks were
311 linked to estrogen response and an estrogen replacement therapy, estradiol. Future studies are
312 required to evaluate the contributions of methylation and *APOE* genotypes to beneficial effects
313 of estrogen as an AD risk-lowering therapy.

314

315 **List of abbreviations:**

316 AD: Alzheimer's Disease, ADAS13: Alzheimer's Disease Assessment Scale – 13 item, ADNI:
317 Alzheimer's Disease Neuroimaging Initiative, BNT30: Boston Naming Test, CDRSB: Clinical
318 Dementia Rating Scale Sum of Boxes, CERAD: Consortium to Establish a Registry for
319 Alzheimer Disease, CpG: cytosine-phosphate-guanine, FAS_animal: animal portion of the
320 Verbal Fluency Test, FHS: Framingham Heart Study, GRM: genetic relatedness matrix, GWAS:
321 genome-wide association study, LDELTOTAL: logical memory - delayed recall, LMD: Logical

322 Memories – Delayed Recall, LMi: Logical Memories – Immediate Recall, MCI: mild cognitive
323 impairment, MRI: magnetic resonance imaging, PASr: Paired Associate Learning – Recognition,
324 PMI: post mortem interval, RAVLT: Rey Auditory Verbal Learning Test, RIN: RNA integrity
325 number, ROSMAP: Religious Orders Study and Rush Memory and Aging Project, RNA-seq:
326 RNA sequencing, SIM: Similarities Test, trailsA: Trail A, VRd: Visual Reproductions – Delayed
327 Recall, WGCNA: weighted gene correlation network analysis

328

329 **Acknowledgements**

330 Not applicable

331

332 **Funding**

333 This study was supported by the National Institute on Aging (NIA) grants, RF1AG057519,
334 R01AG069453, U01AG068057, U19AG068753, P30AG072978, U01AG032984,
335 R56AG069130, R01AG048927, U01AG062602, U01AG058654, RF1AG057768, and
336 RF1AG054156. ROSMAP is supported by P30AG10161, P30AG72975, R01AG15819,
337 R01AG17917, R01AG36042, U01AG46152, and U01AG61356. FHS is supported by National
338 Heart, Lung and Blood Institute (75N92019D00031 and HHSN2682015000011).

339

340 **Availability of data and materials**

341 FHS data are available on the dbGaP (Study Accession ID: phs000056.v5.p3). ROSMAP

342 resources can be requested at from the CommonMind Consortium portal

343 (<http://www.synapse.org>). Data used in preparation of this article were obtained from the

344 Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (<http://adni.loni.usc.edu>). As

345 such, the investigators within the ADNI contributed to the design and implementation of ADNI

346 and/or provided data but did not participate in analysis or writing of this report. A complete
347 listing of ADNI investigators can be found at: [http://adni.loni.usc.edu/wp-](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)
348 [content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf).

349

350 **Authors' contributions**

351 R.P., L.A.F., and G.R.J. conceived overall study design. R.P., K.L., and G.R.J. perceived
352 statistical analysis. R.P., N.P., and J.H. performed data analyses. D.A.B., K.N., and R.A.
353 provided cognitive test and imaging data as well as interpretation of the data from the ROSMAP,
354 ADNI, and FHS, respectively. T.D.S. conducted and provided neuropathological data using
355 autopsied brains. R.P., K.N., D.A.B., T.D.S., L.A.F., and G.R.J. reviewed and edited the
356 manuscript. G.R.J. and L.A.F. supervised and obtained funding for the project.

357

358 **Ethics approval and consent to participate**

359 The study protocol, design, and performance of the current study were approved by the Boston
360 University Institutional Review Board.

361

362 **Consent for publication**

363 Not applicable

364

365 **Competing interests**

366 All authors declare no competing interests.

367

368 **References**

- 369 1. DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease.
370 Molecular Neurodegeneration. 2019;14:32.
- 371 2. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age,
372 sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer
373 disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium.
374 JAMA. 1997;278:1349–1356.
- 375 3. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al.
376 Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset
377 families. Science. 1993;261:921–923.
- 378 4. Reiman EM, Arboleda-Velasquez JF, Quiroz YT, Huentelman MJ, Beach TG, Caselli RJ,
379 et al. Exceptionally low likelihood of Alzheimer's dementia in APOE2 homozygotes from a
380 5,000-person neuropathological study. Nat Commun. 2020;11:1–11.
- 381 5. Panitch R, Hu J, Chung J, Zhu C, Meng G, Xia W, et al. Integrative brain transcriptome
382 analysis links complement component 4 and HSPA2 to the APOE ε2 protective effect in
383 Alzheimer disease. Mol Psychiatry. 2021:1–11.
- 384 6. Jun GR, You Y, Zhu C, Meng G, Chung J, Panitch R, et al. Protein phosphatase 2A and
385 complement component 4 are linked to the protective effect of APOE ε2 for Alzheimer's
386 disease. Alzheimers Dement. 2022. 9 February 2022. <https://doi.org/10.1002/alz.12607>.
- 387 7. Panitch R, Hu J, Xia W, Bennett DA, Stein TD, Farrer LA, et al. Blood and brain
388 transcriptome analysis reveals APOE genotype-mediated and immune-related pathways
389 involved in Alzheimer disease. Alzheimers Res Ther. 2022;14:30.

- 390 8. Bellenguez C, Küçükali F, Jansen IE, Kleindam L, Moreno-Grau S, Amin N, et al. New
391 insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet.*
392 2022;54:412–436.
- 393 9. De Jager P, Srivastava G, Lunnon K, Burgess J, Schalkwyk L, Yu L, et al. Alzheimer's
394 disease pathology is associated with early alterations in brain DNA methylation at ANK1,
395 BIN1, RHBDF2 and other loci. *Nat Neurosci.* 2014;17:1156–1163.
- 396 10. Li QS, Vasanthakumar A, Davis JW, Idler KB, Nho K, Waring JF, et al. Association of
397 peripheral blood DNA methylation level with Alzheimer's disease progression. *Clinical*
398 *Epigenetics.* 2021;13:191.
- 399 11. Foraker J, Millard SP, Leong L, Thomson Z, Chen S, Keene CD, et al. The APOE Gene is
400 Differentially Methylated in Alzheimer's Disease. *J Alzheimers Dis.* 2015;48:745–755.
- 401 12. Walker RM, Vaher K, Bermingham ML, Morris SW, Bretherick AD, Zeng Y, et al.
402 Identification of epigenome-wide DNA methylation differences between carriers of APOE
403 $\epsilon 4$ and APOE $\epsilon 2$ alleles. *Genome Medicine.* 2021;13:1.
- 404 13. Yu L, Lutz MW, Wilson RS, Burns DK, Roses AD, Saunders AM, et al. TOMM40'523
405 variant and cognitive decline in older persons with APOE $\epsilon 3/3$ genotype. *Neurology.*
406 2017;88:661–668.
- 407 14. De Jager PL, Ma Y, McCabe C, Xu J, Vardarajan BN, Felsky D, et al. A multi-omic atlas of
408 the human frontal cortex for aging and Alzheimer's disease research. *Sci Data.*
409 2018;5:180142.
- 410 15. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious
411 Orders Study and Rush Memory and Aging Project. *J Alzheimers Dis.* 2018;64:S161–S189.

- 412 16. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, et al. National
413 Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment
414 of Alzheimer’s disease. *Alzheimers Dement*. 2012;8:1–13.
- 415 17. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta*
416 *Neuropathol*. 1991;82:239–259.
- 417 18. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium
418 to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the
419 neuropathologic assessment of Alzheimer’s disease. *Neurology*. 1991;41:479–486.
- 420 19. Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven
421 approach to preprocessing Illumina 450K methylation array data. *BMC Genomics*.
422 2013;14:293.
- 423 20. Splansky GL, Corey D, Yang Q, Atwood LD, Cupples LA, Benjamin EJ, et al. The Third
424 Generation Cohort of the National Heart, Lung, and Blood Institute’s Framingham Heart
425 Study: Design, Recruitment, and Initial Examination. *American Journal of Epidemiology*.
426 2007;165:1328–1335.
- 427 21. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
428 expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*.
429 2015;43:e47–e47.
- 430 22. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait
431 analysis. *Am J Hum Genet*. 2011;88:76–82.
- 432 23. Jun G, Guo H, Klein BEK, Klein R, Wang JJ, Mitchell P, et al. EPHA2 Is Associated with
433 Age-Related Cortical Cataract in Mice and Humans. *PLoS Genet*. 2009;5:e1000584.

- 434 24. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network
435 analysis. *BMC Bioinformatics*. 2008;9:559.
- 436 25. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and
437 collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics*.
438 2013;14:128.
- 439 26. Folts CJ, Giera S, Li T, Piao X. Adhesion G protein-coupled receptors as drug target for
440 neurological diseases. *Trends Pharmacol Sci*. 2019;40:278–293.
- 441 27. Macke EL, Henningsen E, Jessen E, Zumwalde NA, Landowski M, Western DE, et al. Loss
442 of Chondroitin Sulfate Modification Causes Inflammation and Neurodegeneration in skt
443 Mice. *Genetics*. 2020;214:121–134.
- 444 28. Zhou Y, Liu X, Ma S, Zhang N, Yang D, Wang L, et al. ChK1 activation induces reactive
445 astrogliosis through CIP2A/PP2A/STAT3 pathway in Alzheimer’s disease. *FASEB J*.
446 2022;36:e22209.
- 447 29. Jun G, Vardarajan BN, Buross J, Yu C-E, Hawk MV, Dombroski BA, et al. Comprehensive
448 Search for Alzheimer Disease Susceptibility Loci in the APOE Region. *Arch Neurol*.
449 2012;69:1270–1279.
- 450 30. Zhou Q, Zhao F, Lv Z, Zheng C, Zheng W, Sun L, et al. Association between APOC1
451 Polymorphism and Alzheimer’s Disease: A Case-Control Study and Meta-Analysis. *PLoS*
452 *One*. 2014;9:e87017.
- 453 31. Chiba-Falek O, Gottschalk WK, Lutz MW. The effects of the TOMM40 poly-T alleles on
454 Alzheimer’s disease phenotypes. *Alzheimers Dement*. 2018;14:692–698.
- 455 32. Luine VN. Estradiol and cognitive function: Past, present and future. *Horm Behav*.
456 2014;66:602–618.

- 457 33. Ratnakumar A, Zimmerman SE, Jordan BA, Mar JC. Estrogen activates Alzheimer's
458 disease genes. *Alzheimers Dement (N Y)*. 2019;5:906–917.
- 459 34. Song Y, Li S, Li X, Chen X, Wei Z, Liu Q, et al. The Effect of Estrogen Replacement
460 Therapy on Alzheimer's Disease and Parkinson's Disease in Postmenopausal Women: A
461 Meta-Analysis. *Frontiers in Neuroscience*. 2020;14.
- 462 35. Espeland MA, Shumaker SA, Leng I, Manson JE, Brown CM, LeBlanc ES, et al. Long
463 Term Effects on Cognitive Function of Postmenopausal Hormone Therapy Prescribed to
464 Women Aged 50–55 Years. *JAMA Intern Med*.
465 2013;173:10.1001/jamainternmed.2013.7727.
- 466 36. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive
467 decline: evidence of gene-environment interaction. *Neurology*. 2000;54:1949–1954.
- 468 37. Kunzler J, Youmans KL, Yu C, LaDu MJ, Tai L. APOE modulates the effect of estrogen
469 therapy on A β accumulation EFAD-Tg mice. *Neurosci Lett*. 2014;560:131–136.

470

471 **Figure Legends:**

472 **Figure 1: Differential methylation between AD cases and controls grouped by *APOE* $\epsilon 4$**
473 **carrier status. (a) Study Design.** Methylation array data were obtained from blood (2 datasets)
474 and frozen brain tissue (1 dataset). Methylation of CpG sites was compared between AD cases
475 and controls as well as between *APOE* $\epsilon 4$ carriers and non-carriers. Association of methylation at
476 CpG sites with neuropathological, cognitive and imaging traits was also evaluated. CpG sites
477 with nominally significant P values ($P < 0.05$) between *APOE* $\epsilon 4$ carriers and non-carriers were
478 incorporated in co-methylation network analyses performed separately for data derived from
479 blood and brain. Finally, biological pathways and drug perturbations were identified from

480 analyses of co-methylation networks. Figure created with biorender.com. **(b)** Heatmap showing
481 association of neuropathological traits with methylation at CpG sites that were differentially
482 methylated ($P < 10^{-5}$) between AD cases and controls. CpG sites whose degree of methylation was
483 significantly ($P < 2.0 \times 10^{-3}$) associated with multiple testing correction with at least one trait are
484 indicated by an asterisk. **(c)** Heatmap showing association of cognitive and MRI imaging traits
485 with methylation at CpG sites that were differentially methylated ($P < 10^{-5}$) between AD cases and
486 controls. Direction of differential methylation between AD and controls in *APOE* $\epsilon 4$ carriers or
487 non-carriers in blood was shown. CpG sites whose degree of methylation was significantly
488 associated with at least one trait after multiple testing correction ($P < 1.4 \times 10^{-3}$) are indicated by an
489 asterisk.

490

491 **Figure 2. Differential methylation in the *APOE* region between *APOE* $\epsilon 4$ carriers and non-**
492 **carriers. (a)** Regional plot of the *APOE* region. Differential methylation between $\epsilon 4$ carriers and
493 non-carriers is shown for the total sample (green line), AD cases (blue line), and controls (pink
494 line) across three datasets. X-axis represents CpG sites that were significantly differentially
495 methylated between *APOE* $\epsilon 4$ carriers and non-carriers at a genome-wide significance level
496 ($P < 5 \times 10^{-8}$). Y-axis indicates the log₁₀ P-value of hypermethylation (> 0) or hypomethylation ($<$
497 0). **(b)** Heatmap showing association of methylation in brain with expression of *APOE* and
498 adjacent genes. Significant ($P < 0.05$) associations are indicated by an asterisk. **(c)** Heatmap
499 showing association of methylation in blood with cognitive test scores in the FHS dataset.
500 Significant ($P < 0.05$) associations are indicated by an asterisk.

501

502 **Figure 3. Co-methylation networks.** Co-methylation networks included genes with
503 significantly differentially methylated CpG sites ($P < 0.05$) between *APOE* $\epsilon 4$ carriers and non-
504 carriers. Bar plots indicate significant AD and *APOE* genotype-related co-methylation networks
505 containing genes enriched for **(a)** biological pathways and **(b)** drug perturbation gene-sets (i.e.,
506 genes whose expression is modified by a drug). Networks with significant pathway or drug gene-
507 set enrichment (adjusted $P < 0.05$) are shown. (c) Biological subnetwork including genes from
508 multiple co-methylation networks enriched for genes whose expression is perturbed by estradiol.

Table 1. Differentially methylated CpG sites in brain for AD in total, *APOE* ϵ 4 carriers, and non-carriers

CpG Name	Chr	Position	Gene	Total Sample		<i>APOE</i> ϵ 4 carriers		<i>APOE</i> ϵ 4 non-carriers	
				T	P	T	P	T	P
cg19533050	2	163175044	IFIH1	-1.23	0.22	-4.92	1.9×10^{-6}	0.35	0.73
cg23808213	2	166948291	SCN1A	-4.81	1.9×10^{-6}	-1.17	0.24	-4.71	3.2×10^{-6}
cg05731218	2	216769199	intergenic	-7.06	4.2×10^{-12}	-2.97	3.3×10^{-3}	-5.15	3.7×10^{-7}
cg04436449	3	185214835	TMEM41A	-4.43	1.1×10^{-5}	-0.56	0.57	-4.62	4.9×10^{-6}
cg12307200	3	188664632	intergenic	-7.04	4.7×10^{-12}	-4.48	1.3×10^{-5}	-4.87	1.5×10^{-6}
cg16234490	4	77138082	FAM47E	-4.48	8.6×10^{-6}	0.17	0.87	-4.97	9.2×10^{-7}
cg24899806	7	119914282	KCND2	-3.77	1.8×10^{-4}	0.22	0.83	-4.51	8.2×10^{-6}
cg23831517	8	34182528	intergenic	4.25	2.5×10^{-5}	-0.63	0.53	4.63	4.5×10^{-6}
cg14096074	9	34255149	KIF24	-4.40	1.3×10^{-5}	-0.99	0.32	-4.66	4.0×10^{-6}
cg03727169	10	31418969	intergenic	-4.67	3.6×10^{-6}	-1.60	0.11	-4.94	1.1×10^{-6}
cg01982597	10	50733420	ERCC6	-4.10	4.7×10^{-5}	0.54	0.59	-4.64	4.4×10^{-6}
cg20326704	10	70321770	TET1	-1.57	0.12	-4.61	7.6×10^{-6}	0.27	0.79
cg04126866	10	85932763	C10orf99	-5.24	2.2×10^{-7}	-1.84	0.07	-4.59	5.5×10^{-6}
cg14882481	11	107437051	ALKBH8	-4.54	6.7×10^{-6}	0.19	0.85	-4.89	1.4×10^{-6}
cg10907744	12	131589455	GPR133	4.97	8.6×10^{-7}	2.56	0.01	4.56	6.4×10^{-6}
cg18708502	13	21588555	LATS2	4.19	3.1×10^{-5}	-0.18	0.86	4.50	8.4×10^{-6}
cg16746221	14	20666088	OR11G2	-3.86	1.2×10^{-4}	-1.15	0.25	-4.49	8.7×10^{-6}
cg24231804	15	67316861	intergenic	-5.53	4.5×10^{-8}	-1.73	0.09	-4.68	3.7×10^{-6}
cg14829066	15	88559141	NTRK3	-4.66	3.8×10^{-6}	-1.06	0.29	-5.15	3.7×10^{-7}
cg19987111	15	101747167	CHSY1	4.10	4.6×10^{-5}	-1.65	0.10	4.75	2.7×10^{-6}
cg02432274	16	88378468	intergenic	2.00	0.05	4.68	5.5×10^{-6}	0.02	0.98
cg05952786	17	48559485	RSAD1	-5.11	4.2×10^{-7}	-1.67	0.10	-4.87	1.5×10^{-6}
cg15503752	17	74639731	ST6GALNAC1	4.40	1.2×10^{-5}	-0.52	0.60	4.62	4.9×10^{-6}
cg05421550	19	4446485	UBXN6	-4.88	1.3×10^{-6}	-1.66	0.10	-5.11	4.6×10^{-7}
cg19612770	19	4475216	HDGF2	-4.82	1.7×10^{-6}	-1.49	0.14	-4.73	2.9×10^{-6}

Only CpG sites moderately ($P < 10^{-5}$) differentially methylated in either *APOE* ϵ 4 carriers and/or non-carriers were included.

T: T-value, P: P-value

Table 2. Differentially methylated CpG sites in brain for *APOE* ϵ 4 status in total, AD cases, and controls

CpG Name	Chr	Position	Source	Gene	Total Sample		AD		Control	
					T	P	T	P	T	P
cg05002071	11	76510323	FHS (blood)	<i>intergenic</i>	5.67	1.5x10 ⁻⁸	NA	NA	5.67	1.5x10 ⁻⁸
cg02613937	19	45395297	ROSMAP (brain)	<i>TOMM40</i>	-7.55	1.3x10 ⁻¹³	-7.41	7.0x10 ⁻¹³	-3.26	1.3x10 ⁻³
cg14123992	19	45407868	ROSMAP (brain)	<i>APOE</i>	6.74	3.4x10 ⁻¹¹	6.51	2.2x10 ⁻¹⁰	2.93	3.7x10 ⁻³
cg04406254	19	45407945	ROSMAP (brain)	<i>APOE</i>	6.05	2.4x10 ⁻⁹	5.90	7.4x10 ⁻⁹	2.45	0.02
cg06750524	19	45409955	FHS (blood)	<i>APOE</i>	6.45	1.1x10 ⁻¹⁰	NA	NA	6.45	1.1x10 ⁻¹⁰
cg23270113	19	45417587	FHS (blood)	<i>APOC1</i>	-6.40	1.5x10 ⁻¹⁰	NA	NA	-6.40	1.5x10 ⁻¹⁰
cg07773593	19	45417793	ADNI (blood)	<i>APOC1</i>	-6.04	4.6x10 ⁻⁹	-3.00	3.6x10 ⁻³	-4.36	2.1x10 ⁻⁵
cg05644480	19	45418020	FHS (blood)	<i>APOC1</i>	-5.85	5.0x10 ⁻⁹	NA	NA	-5.85	5.0x10 ⁻⁹


T: T-value, P: P-value. Only CpG sites significantly ($P < 5 \times 10^{-8}$) differentially methylated between *APOE* ϵ 4 carriers and non-carriers in the total sample were included.

Table 3. Summary of co-methylated networks from ROSMAP and ADNI associated with AD and *APOE* ϵ 4 status


Module Name	Dataset	Size	AD P-value*	<i>APOE</i> P-value*	significant (FDR < 0.05) hallmark pathways	Significant (FDR < 0.05) drug perturbations
Mod1	ROSMAP	288	0.03	2.0×10^{-4}	NA	NA
Mod2	ROSMAP	6395	2.6×10^{-4}	3.1×10^{-5}	UV Response Dn, Complement, Epithelial Mesenchymal Transition, Mitotic Spindle, Apical Junction, TGF-beta Signaling, Estrogen Response Early, Coagulation	estradiol
Mod3	ROSMAP	4891	2.9×10^{-3}	6.1×10^{-4}	Coagulation, Myogenesis, UV Response Dn, Estrogen Response Early, Epithelial Mesenchymal Transition, Notch Signaling	estradiol, mycophenolate mofetil
Mod4	ROSMAP	3043	2.4×10^{-3}	4.9×10^{-3}	Myogenesis, Estrogen Response Early	estradiol, letrozole
Mod5	ROSMAP	1277	0.02	1.1×10^{-9}	E2F Targets	imatinib, methotrexate, bexarotene, fulvestrant, estradiol, etoposide, tamoxifen, hydroquinone, docetaxel, paclitaxel, valproic acid, ethanol, plicamycin
Mod6	ADNI	391	0.04	5.3×10^{-4}	NA	NA
Mod7	ADNI	148	0.04	0.04	NA	NA
Mod8	ADNI	4167	4.0×10^{-3}	0.01	UV Response Dn, Estrogen Response Early, Myogenesis, Apical Junction	doxorubicin, tamoxifen, cisplatin, estradiol, prednisolone, valproic acid, ethanol, rosiglitazone, plicamycin, carboplatin, paclitaxel, hydrocortisone, dexamethasone

*AD and *APOE* P-values derived from student's t-test between conditions of module eigenvalues which indicate average methylation over the network.


a




b




c



a



b



c

